Cramer: Real Opportunity in This Drug Maker

NPS Pharmaceuticals CEO on Gattex's FDA Approval

NPS Pharmaceuticals CEO Dr. Francois Nader discusses the approval of its short bowel syndrome drug Gattex, and what's next for the company.

"It's speculative, but given their main drug has been approved and the stock's barely budged, I think we could have a real opportunity here," said Jim Cramer on Monday's broadcast.

The stock that's captured Cramer's interest is NPS Pharmaceuticals.

"The stock hasn't rallied much, yet there have been some major positive developments," said Cramer.

On December 21st, NPS received FDA approval for Gattex, which is their treatment for an ultra-rare orphan condition called short-bowel syndrome where patients need to be fed intravenously for 10 to 12 hours a day because their intestines can't properly absorb nutrients.

Even though only a few thousand people have this condition, Gattex could potentially generate $350 million in peak sales.

Sean Russell | Getty Images

Although stocks such as these are higher risk investments, Cramer said, "When you consider that NPS has a market cap of $775 million, the stock seems cheap in light of the potential opportunity."

And he added, the company makes another drug that could generate gains as well.

"NPS has another one in the pipeline, a treatment for hypo-parathoidism, which could be approved by the middle of next year."

All told, "I think we could have a real opportunity here," said Cramer.

Hear more from Dr. Francois Nader, President and CEO of NPS Pharmaceuticals in the video above.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? [e-mail]

Questions, comments, suggestions for the "Mad Money" website? [e-mail]